Association of Plasma High-Density Lipoprotein Cholesterol Level With Risk of Fractures in Healthy Older Adults.


Journal

JAMA cardiology
ISSN: 2380-6591
Titre abrégé: JAMA Cardiol
Pays: United States
ID NLM: 101676033

Informations de publication

Date de publication:
01 03 2023
Historique:
pmc-release: 18 01 2024
medline: 19 4 2023
pubmed: 19 1 2023
entrez: 18 1 2023
Statut: ppublish

Résumé

Increased levels of high-density lipoprotein cholesterol (HDL-C) have been associated with osteoporosis. Preclinical studies have reported that HDL-C reduces bone mineral density by reducing osteoblast number and function. However, the clinical significance of these findings is unclear. To determine whether higher HDL-C levels are predictive of an increased fracture risk in healthy older adults. This cohort study is a post hoc analysis of data from the Aspirin in Reducing Events in the Elderly (ASPREE) clinical trial and the ASPREE-Fracture substudy. ASPREE was a double-blind, randomized, placebo-controlled primary prevention trial of aspirin that recruited participants between 2010 and 2014. These comprised community-based older adults (16 703 Australians aged ≥70 years, 2411 US participants ≥65 years) without evident cardiovascular disease, dementia, physical disability, and life-limiting chronic illness. The ASPREE-Fracture substudy collected data on fractures reported postrandomization from Australian participants. Cox regression was used to calculate hazard ratio (HR) and 95% CI. Data analysis for this study was performed from April to August 2022. Plasma HDL-C. Fractures included were confirmed by medical imaging and included both traumatic and minimal trauma fractures. Fractures were adjudicated by an expert review panel. Of the 16 262 participants who had a plasma HDL-C measurement at baseline (8945 female participants [55%] and 7319 male [45%]), 1659 experienced at least 1 fracture over a median (IQR) of 4.0 years (0.02-7.0 years). In a fully adjusted model, each 1-SD increment in HDL-C level was associated with a 14% higher risk of fractures (HR, 1.14; 95% CI, 1.08-1.20). The results remained similar when these analyses were stratified by sex. Sensitivity and stratified analyses demonstrated that these associations persisted when the analyses were repeated to include only (1) minimal trauma fractures, (2) participants not taking osteoporosis medications, (3) participants who were never smokers and reported that they did not drink alcohol, and (4) participants who walked outside for less than 30 minutes per day and reported no participation in moderate/vigorous physical activity and to examine only (5) statin use. No association was observed between non-HDL-C levels and fractures. This study suggests that higher levels of HDL-C are associated with an increased fracture risk. This association was independent of common risk factors for fractures.

Identifiants

pubmed: 36652261
pii: 2800308
doi: 10.1001/jamacardio.2022.5124
pmc: PMC9857824
doi:

Substances chimiques

Cholesterol, HDL 0
Cholesterol 97C5T2UQ7J
Aspirin R16CO5Y76E

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

268-272

Subventions

Organisme : NIA NIH HHS
ID : U01 AG029824
Pays : United States
Organisme : NIA NIH HHS
ID : U19 AG062682
Pays : United States

Commentaires et corrections

Type : CommentIn

Auteurs

Sultana Monira Hussain (SM)

School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
Department of Medical Education, Melbourne Medical School, University of Melbourne, Melbourne, Victoria, Australia.

Peter R Ebeling (PR)

Department of Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Victoria, Australia.

Anna L Barker (AL)

School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
Silverchain, Melbourne, Victoria, Australia.

Lawrence J Beilin (LJ)

Medical School, Royal Perth Hospital, University of Western Australia, Perth, Western Australia, Australia.

Andrew M Tonkin (AM)

School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.

John J McNeil (JJ)

School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH